Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
Objective: This presentation focuses on neuroimaging of the Dopamine Transporter as an enrichment biomarker in clinical trials of Parkinson's disease (PD). Background: The Critical Path…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)
Objective: The path is summarized that led to the creation of a global public-private-partnership uniting an international non-profit charity, Parkinson's UK, a global non-profit organization,…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale
Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)
Objective: The aim of this study was to evaluate the impact of STN DBS on RS parameters in PD. We have compared disease progression in…
- « Previous Page
- 1
- …
- 32
- 33
- 34